Adeno-Associated Virus-Mediated Dorsal Root Ganglion Toxicity in the New Zealand White Rabbit.

AAV dorsal root ganglia gene therapy toxicity

Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
22 Feb 2024
Historique:
medline: 22 2 2024
pubmed: 22 2 2024
entrez: 22 2 2024
Statut: aheadofprint

Résumé

Recombinant adeno-associated virus (AAV)-mediated degeneration of sensory neurons in the dorsal root ganglia (DRG) and trigeminal ganglia (TG) has been observed in non-human primates (NHPs) following intravenous (IV) and intrathecal (IT) delivery. Administration of recombinant AAV encoding a human protein transgene via a single intra-cisterna magna (ICM) injection in New Zealand white rabbits resulted in histopathology changes very similar to NHPs: mononuclear cell infiltration, degeneration/necrosis of sensory neurons, and nerve fiber degeneration of sensory tracts in the spinal cord and of multiple nerves. AAV-associated clinical signs and incidence/severity of histologic findings indicated that rabbits were equally or more sensitive than NHPs to sensory neuron damage. Another study using human and rabbit transgene constructs of the same protein demonstrated comparable changes suggesting that the effects are not an immune response to the non-self protein transgene. Rabbit has not been characterized as a species for general toxicity testing of AAV gene therapies, but these studies suggest that it may be an alternative model to investigate mechanisms of AAV-mediated neurotoxicity and test novel AAV designs mitigating these adverse effects.

Identifiants

pubmed: 38385340
doi: 10.1177/01926233241229808
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1926233241229808

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors were employed by Biogen (except for Claudine Tremblay) at the time of their contribution to this work.

Auteurs

Eric Tien (E)

Biogen Inc., Cambridge, Massachusetts, USA.

Branka Grubor (B)

Biogen Inc., Cambridge, Massachusetts, USA.

Melissa Kirkland (M)

Biogen Inc., Cambridge, Massachusetts, USA.

Su Jing Chan (SJ)

Voyager Therapeutics, Inc., Lexington, Massachusetts, USA.

Nick van der Munnik (N)

GlaxoSmithKline, Middlesex, UK.

Wenlong Xu (W)

Sonata Therapeutics, Watertown, Massachusetts, USA.

Kate Henry (K)

Biogen Inc., Cambridge, Massachusetts, USA.

Stefan Hamann (S)

Biogen Inc., Cambridge, Massachusetts, USA.

Cong Wei (C)

Biogen Inc., Cambridge, Massachusetts, USA.

Wan-Hung Lee (WH)

Biogen Inc., Cambridge, Massachusetts, USA.

Davide Gianni (D)

Biogen Inc., Cambridge, Massachusetts, USA.

Ashton Brennecke (A)

Biogen Inc., Cambridge, Massachusetts, USA.

Kalyani Nambiar (K)

Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

Jeron Chen (J)

Voyager Therapeutics, Inc., Lexington, Massachusetts, USA.

Bin Liu (B)

Vertex, Boston, Massachusetts, USA.

Shen Shen (S)

Vertex, Boston, Massachusetts, USA.

Claudine Tremblay (C)

Charles River Laboratories, Montreal, Quebec, Canada.

Edward D Plowey (ED)

Biogen Inc., Cambridge, Massachusetts, USA.

Patrick Trapa (P)

Biogen Inc., Cambridge, Massachusetts, USA.

James Fikes (J)

Biogen Inc., Cambridge, Massachusetts, USA.

Junghae Suh (J)

Biogen Inc., Cambridge, Massachusetts, USA.

Dale Morris (D)

Biogen Inc., Cambridge, Massachusetts, USA.

Classifications MeSH